Contact us today to secure your position as a partner, sponsor or exhibitor at the show.
This event is an opportunity to showcase your services to your target market. By sponsoring our event, you can develop relationships, make sales and raise your company's profile.
Sponsoring involves more than just a two day event. We have access to the Total BioPharma community of almost 250,000 people. You provide us with great content, and we'll distribute it through email, our blog and multiple social media channels.
Your success at the show is dependent on the quality relationships you build. Take a look at the delegate list before the event, decide who you want to meet and we'll make it happen.
Upstream cell culture is the single, most critical process in developing safe and efficacious biologics and vaccines; the therapies of the future for unmet medical needs. Yet it is volatile as it is expensive since it depends on living material for cure.
This 4th annual Cell Culture World Congress USA is part of Terrapinn’s cell culture global series that brings together Heads, Principal Investigators, Scientists and Engineers from biopharmaceutical companies’ upstream cell culture divisions, to share and learn from each other novel and innovative strategies to streamline and manage cell culture processes better.
We have a proud track record in the upstream cell culture space, with an established presence in the US, Europe and Asia. This event is the event where you can find out what’s new, how it’s done and who is doing it in 2015. This is just a sample of who has joined us at our events in the past.
At the 2014 World Drug Safety Congress Americas, Anne Wolka, Eli Lilly and Company, gave a presentation on “New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment”. Download and learn: The rebirth of the PSUR Objective of the PBRER Critical Analysis of Benefits Critical Analysis of Risks Integrated Benefit-Risk Analysis Impact of the PBRER So What Is a […]
The post New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment appeared first on Total Biopharma.
The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with the likes of Volkswagen and Samsung who’s spends were around $11 […]
Earlier this year at BioPharma Asia Convention, when we spoke to some speakers about their thoughts on the key growth strategy that Asian biotech companies should adopt, there seemed to be a unanimous agreement that looking beyond Asia is the way to go. “Biotech companies in Asia have to think globally, and link globally. “ […]
Innovation and strategy for pharmaceutical, biotech and R&D